US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Weight Loss Drugs

1,229.17

-22.0642-1.76%

Number of Gainers:3

Number of Losers:4

Number of Flat:- -

PE:- -

High:1,257.62

Open:1,252.13

Low:1,216.60

Close:1,251.24

Loading ...

Eli Lilly Says Orforglipron Met Primary Endpoint in Diabetes, Obesity Trial; Shares Gain Pre-Bell

MT Newswires Live

Eli Lilly's Mounjaro Launch Triggers Weight-Loss Drug Craze In India, Novo Nordisk Seeks To Move Up Wegovy Launch

Eli Lilly - Expects to Submit Orforglipron for Weight Management, Submission for Treatment of Type 2 Diabetes Anticipated in 2026

THOMSON REUTERS

Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial

Analysts Conflicted on These Healthcare Names: Novo Nordisk (NVO) and Sanofi (OtherSNYNF)

BRIEF-ACIP Votes To Expand Recommendation For Pfizer’S RSV Vaccine Abrysvo To Include Adults Aged 50 To 59 At Increased Risk Of Disease

ACIP votes to expand recommendation for Pfizer’s RSV vaccine

Acip Votes to Expand Recommendation for Pfizer’s Rsv Vaccine Abrysvo® to Include Adults Aged 50 to 59 at Increased Risk of Disease

THOMSON REUTERS

Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025

Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®

Top Cancer Stocks to Buy to Boost Your Portfolio's Health

Viking Therapeutics’ VK2735: A Promising Contender Amidst Pfizer’s Setback

Trump signs healthcare executive order that includes a win for pharma companies

Trump Signs Healthcare Executive Order Seeking Changes to US Medicare Drug Price Negotiation Process

THOMSON REUTERS

Counterfeit Ozempic Identified in US Supply Chain With Fake Labels And Needles, FDA Alerts

European pharma companies issue demands to stay in EU ahead of expected US tariffs

NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback

BRIEF-Skye Bioscience Demonstrates Over 30% Weight Loss With Nimacimab And Tirzepatide Combination In Preclinical Model

BUZZ-Skye Bioscience rises after experimental weight-loss drug shows promise in mice

Eli Lilly and Company (LLY): One of the High Growth Forever Dividend Stocks to Invest In

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4599/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4599","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","market":"US","secType":"PLATE","nameCN":"Weight Loss Drugs","latestPrice":1229.1708,"timestamp":1745265599999,"preClose":1251.235,"halted":0,"volume":57826241,"delay":0,"changeRate":-0.017634,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-22.064209,"latestTime":"04-21 16:00:00 EDT","open":1252.1276,"high":1257.6151,"low":1216.6044,"amount":4848730365.862926,"amplitude":0.032776,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745308800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":9.286466,"peRate":32.45662,"turnoverRate":0.005474,"increases":3,"decrements":4,"flats":0,"marketCap":1310903118528,"floatMarketCap":1235170757472},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","high":1257.6151,"amplitude":0.032776,"preClose":1251.235,"low":1216.6044,"pbRate":"9.286466","latestPrice":1229.1708,"volume":57826241,"delay":0,"open":1252.1276,"prevYearClose":1305.0607,"prevWeekClose":1251.235,"prevMonthClose":1314.3724,"prevQuarterClose":1314.3724,"fiveDayClose":1177.7317,"twentyDayClose":1358.6935,"sixtyDayClose":1290.7499,"secType":"PLATE","market":"US","turnoverRate":0.005474,"peRate":32.45662,"marketCap":1310903118528,"floatMarketCap":1235170757472,"timestamp":1745265599999,"nameCN":"Weight Loss Drugs"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4599\",,,,undefined,":{"bkCode":"BK4599","up":3,"down":4,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4599\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2528797607","title":"Eli Lilly Says Orforglipron Met Primary Endpoint in Diabetes, Obesity Trial; Shares Gain Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2528797607","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528797607?lang=en_us&edition=fundamental","pubTime":"2025-04-17 18:51","pubTimestamp":1744887089,"startTime":"0","endTime":"0","summary":"Eli Lilly Says Orforglipron Met Primary Endpoint in Diabetes, Obesity Trial; Shares Gain Pre-Bell","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LLY","LU1868836914.USD","LU1989771016.USD","LU2237443382.USD","SG9999018857.SGD","BK4534","LU2552382132.HKD","IE00BFTCPJ56.SGD","LU0943347566.SGD","IE0004445239.USD","LU2552382058.USD","SG9999014880.SGD","LU0882574139.USD","IE00BJT1NW94.SGD","LU1868836757.USD","LU1057294990.SGD","LU1061106388.HKD","LU0820561818.USD","LU1720051017.SGD","LU1868837136.USD","LU0689472784.USD","LU1868836591.USD","LU0203201768.USD","LU0471298694.HKD","LU0823416689.USD","LU2237438978.USD","SG9999015986.USD","LU1974910355.USD","LU0097036916.USD","IE00B1BXHZ80.USD","LU0708995401.HKD","BK4599","LU2023250504.SGD","LU0106261372.USD","LU2237443622.USD","LU0289739699.SGD","LU0122379950.USD","LU1868837300.USD","LU0203202063.USD","LU2237443549.SGD","BK4533","SGXZ57979304.SGD","LU0466842654.USD","LU2237443978.SGD","LU2552382215.SGD","LU0061475181.USD","LU1093756325.SGD","LU0320765059.SGD","LU0820561909.HKD","LU2264538146.SGD"],"gpt_icon":0},{"id":"2528153347","title":"Eli Lilly's Mounjaro Launch Triggers Weight-Loss Drug Craze In India, Novo Nordisk Seeks To Move Up Wegovy Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2528153347","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528153347?lang=en_us&edition=fundamental","pubTime":"2025-04-17 18:45","pubTimestamp":1744886726,"startTime":"0","endTime":"0","summary":"Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.In March this year, U.S. pharma giant Eli Lilly And Co  announced the launch of its popular weight loss drug Mounjaro  in India, which is expected to have the second-largest population of overweight or obese people by 2050.Deloitte's fastest-growing software company partners with Amazon, Walmart & Target – Last Chance to get 4,000 of its pre-IPO shares for just $0.26/share!See Also: This investment company boasts a 33.85% internal rate of return  for its realized projects, allowing accredited investors to earn passive returns and avoid the headaches of being a landlord.Lakdawala also said Eli Lilly will have an early lead over Novo Nordisk’s Wegovy. Wegovy contains semaglutide, the same ingredient as its diabetes drug Ozempic—a medication often used off-label for weight loss.Novo may also have to price Wegovy more competitively in India. Mounjaro, a once-weekly injection approved by Indi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/eli-lillys-mounjaro-launch-triggers-104526470.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IRR","LU1280957306.USD","SG9999014906.USD","LU1804176565.USD","IE00BK4W5L77.USD","LU1057294990.SGD","BK4516","BK4581","LU2357305700.SGD","LU1712237335.SGD","LU0256863902.USD","LU1093756168.USD","SG9999015952.SGD","LU1983299246.USD","LU2023250504.SGD","IE00BFTCPJ56.SGD","SG9999018857.SGD","LU2106854487.HKD","LU0289739699.SGD","LU2112291526.USD","LU2265009873.SGD","LU1868837300.USD","LU2471134523.USD","BK4533","LU1093756325.SGD","LLY","BK4599","IE00B2B36J28.USD","LU1551013342.USD","LU0094547139.USD","LU1061106388.HKD","IE00BJJMRZ35.SGD","LU2361044865.SGD","LU0203201768.USD","LU0466842654.USD","NVO","SGXZ99366536.SGD","SG9999014880.SGD","LU1267930730.SGD","LU2264538146.SGD","LU1291159041.SGD","SG9999017495.SGD","SG9999015945.SGD","IE00BKVL7J92.USD","LU2324357040.USD","IE00B4R5TH58.HKD","IE00BJLML261.HKD","LU2552382132.HKD","LU0256863811.USD","LU0096364046.USD"],"gpt_icon":1},{"id":"2528797874","title":"Eli Lilly - Expects to Submit Orforglipron for Weight Management, Submission for Treatment of Type 2 Diabetes Anticipated in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2528797874","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528797874?lang=en_us&edition=fundamental","pubTime":"2025-04-17 18:45","pubTimestamp":1744886703,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nTUA73V7TJ:9","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2361045086.USD","SG9999001176.SGD","LU0256863902.USD","LU0385154629.USD","LLY","LU2468319806.SGD","SG9999001176.USD","LU0122379950.USD","LU0820561818.USD","LU0354030511.USD","LU1814569148.SGD","LU0320765059.SGD","LU2237443549.SGD","LU2750360997.AUD","BK4516","IE00B1BXHZ80.USD","LU1868836591.USD","LU0109391861.USD","LU0097036916.USD","LU1366192091.USD","IE00BJJMRZ35.SGD","SGXZ99366536.SGD","LU2237443622.USD","LU1093756325.SGD","SGXZ51526630.SGD","BK4599","IE00B4R5TH58.HKD","LU1551013425.SGD","LU2491049909.HKD","LU1267930730.SGD","LU1868836914.USD","LU0289739699.SGD","LU2265009873.SGD","SG9999015952.SGD","LU2360106947.USD","LU2471134523.USD","SG9999017495.SGD","LU2602419157.SGD","LU0456855351.SGD","SG9999015945.SGD","LU1061106388.HKD","LU2361044865.SGD","LU0058720904.USD","LU0466842654.USD","LU1983299246.USD","LU0354030438.USD","LU0882574055.USD","LU0417517546.SGD","LU2552382215.SGD","LU0114720955.EUR"],"gpt_icon":0},{"id":"2528373790","title":"Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2528373790","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528373790?lang=en_us&edition=fundamental","pubTime":"2025-04-17 18:45","pubTimestamp":1744886700,"startTime":"0","endTime":"0","summary":"Orforglipron is the first small molecule GLP-1 to successfully complete a Phase 3 trial, lowering A1C by an average of 1.3% to 1.6% across doses. The overall safety and tolerability profile oforforglipron in ACHIEVE-1 was consistent with injectable GLP-1 therapies. In the first Phase 3 trial of the ACHIEVE program, orforglipron met the primary endpoint of superior A1C reduction compared to placebo at 40 weeks, lowering A1C by an average of 1.3% to 1.6% from a baseline of 8.0%, using the efficacy estimand.2 In a key secondary endpoint, more than 65% of participants taking the highest dose of orforglipron achieved an A1C less than or equal to 6.5%, which is below the American Diabetes Association's  defined threshold for diabetes.3 In an additional key secondary endpoint, participants taking orforglipron lost an average of 16.0 lbs  at the highest dose. Given that participants had not yet reached a weight plateau at the time the study ended, it appears that full weight reduction was not ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/lillys-oral-glp-1-orforglipron-104500810.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lillys-oral-glp-1-orforglipron-104500810.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0122379950.USD","LU0820561818.USD","LU1232071149.USD","BK4144","LU2552382058.USD","LU0882574055.USD","LU0289739699.SGD","LLY","LU1551013425.SGD","IE00B1BXHZ80.USD","LU0061475181.USD","IE00BK4W5L77.USD","LU2264538146.SGD","LU0820561909.HKD","SG9999015978.USD","LU2361044949.HKD","LU2237438978.USD","LU2602419157.SGD","SGXZ81514606.USD","LU0882574139.USD","SGXZ31699556.SGD","SGXZ99366536.SGD","LU2237443465.HKD","LU2237443978.SGD","SG9999015945.SGD","BK4590","LU1868836591.USD","LU0238689110.USD","LU0097036916.USD","LU0096364046.USD","LU1061106388.HKD","LU1712237335.SGD","IE00BJLML261.HKD","LU0198837287.USD","LU0354030511.USD","GLP","LU2491050071.SGD","LU0417517546.SGD","LU2023250504.SGD","SGXZ51526630.SGD","BK4585","LU2112291526.USD","LU0640476718.USD","LU0094547139.USD","LU2750360641.GBP","BK4599","SG9999014880.SGD","LU2324357040.USD","LU1983299246.USD","LU1280957306.USD"],"gpt_icon":1},{"id":"2528762635","title":"Analysts Conflicted on These Healthcare Names: Novo Nordisk (NVO) and Sanofi (OtherSNYNF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2528762635","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528762635?lang=en_us&edition=fundamental","pubTime":"2025-04-17 16:55","pubTimestamp":1744880109,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Novo Nordisk (NVO – Research Report) and Sanofi (S...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-novo-nordisk-nvo-and-sanofi-othersnynf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-novo-nordisk-nvo-and-sanofi-othersnynf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","NVO","HCSG","BK4532","BK4599","BK4585","LU1093756325.SGD","BK4007","LU0154236417.USD","BK4588","LU1093756168.USD","SNYNF"],"gpt_icon":0},{"id":"2528704562","title":"BRIEF-ACIP Votes To Expand Recommendation For Pfizer’S RSV Vaccine Abrysvo To Include Adults Aged 50 To 59 At Increased Risk Of Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2528704562","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528704562?lang=en_us&edition=fundamental","pubTime":"2025-04-17 04:32","pubTimestamp":1744835523,"startTime":"0","endTime":"0","summary":"BRIEF-ACIP Votes To Expand Recommendation For Pfizer’S RSV Vaccine Abrysvo To Include Adults Aged 50 To 59 At Increased Risk Of DiseaseApril 16 (Reuters) - Pfizer Inc PFE.N:ACIP VOTES TO EXPAND RECOMM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nTUA5KWNWL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","LU0225284248.USD","LU0456855351.SGD","LU0306806265.USD","SG9999011175.SGD","IE00BBT3K403.USD","SG9999013999.USD","SGXZ57979304.SGD","SG9999003800.SGD","LU1883839398.USD","LU1894683264.USD","LU0289739699.SGD","LU0234572021.USD","BK4568","SG9999002232.USD","LU0306807586.USD","IE00BLSP4239.USD","BK4588","LU1023059063.AUD","PFE","BK4592","SG9999001176.SGD","LU0321505439.SGD","BK4585","LU1894683348.USD","LU0170899867.USD","BK4599","IE0002270589.USD","BK4533","LU0122379950.USD","IE00B19Z3B42.SGD","SG9999001176.USD","SG9999002224.SGD","LU1057294990.SGD","LU0058720904.USD","BK4534","LU0225771236.USD","IE000M9KFDE8.USD","IE00B19Z3581.USD","LU1066053197.SGD","BK4007","IE00BLSP4452.SGD","LU0868494617.USD","LU1066051498.USD","LU0985481810.HKD","LU0321505868.SGD","BK4581"],"gpt_icon":0},{"id":"2528089912","title":"ACIP votes to expand recommendation for Pfizer’s RSV vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2528089912","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528089912?lang=en_us&edition=fundamental","pubTime":"2025-04-17 04:20","pubTimestamp":1744834835,"startTime":"0","endTime":"0","summary":"Pfizer (PFE) announced that the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand its ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/acip-votes-to-expand-recommendation-for-pfizers-rsv-vaccine?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/acip-votes-to-expand-recommendation-for-pfizers-rsv-vaccine?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4550","LU0321505868.SGD","LU0225284248.USD","LU1023059063.AUD","IE000M9KFDE8.USD","LU1066053197.SGD","IE00BLSP4452.SGD","LU0225771236.USD","BK4534","SG9999003800.SGD","IE0002270589.USD","SG9999013999.USD","LU0122379950.USD","BK4581","BK4585","IE00BLSP4239.USD","LU0306807586.USD","LU1894683264.USD","LU0234572021.USD","SG9999002232.USD","LU0058720904.USD","LU0289739699.SGD","SG9999011175.SGD","IE00B19Z3B42.SGD","LU1894683348.USD","BK4599","BK4588","BK4007","IE00BBT3K403.USD","BK4568","SGXZ57979304.SGD","PFE","SG9999001176.USD","IE00B19Z3581.USD","BK4592","LU0321505439.SGD","LU1066051498.USD","LU0306806265.USD","SG9999002224.SGD","LU0868494617.USD","LU0985481810.HKD","LU1883839398.USD","SG9999001176.SGD","LU0170899867.USD","LU1057294990.SGD","LU0456855351.SGD","BK4533"],"gpt_icon":0},{"id":"2528227722","title":"Acip Votes to Expand Recommendation for Pfizer’s Rsv Vaccine Abrysvo® to Include Adults Aged 50 to 59 at Increased Risk of Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2528227722","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528227722?lang=en_us&edition=fundamental","pubTime":"2025-04-17 04:15","pubTimestamp":1744834501,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nTUA5KWNWL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","IE00B19Z3B42.SGD","LU0122379950.USD","BK4585","BK4533","IE00BLSP4452.SGD","LU0234572021.USD","SG9999001176.USD","LU0170899867.USD","BK4550","LU0985481810.HKD","LU1883839398.USD","IE000M9KFDE8.USD","LU0456855351.SGD","SG9999011175.SGD","LU1066053197.SGD","IE00B19Z3581.USD","LU1066051498.USD","LU0306806265.USD","SG9999002232.USD","LU1023059063.AUD","LU1057294990.SGD","BK4534","BK4592","LU0225771236.USD","SGXZ57979304.SGD","SG9999003800.SGD","IE00BLSP4239.USD","BK4599","BK4581","IE00BBT3K403.USD","LU0225284248.USD","SG9999001176.SGD","LU0058720904.USD","LU1894683348.USD","PFE","LU0306807586.USD","LU0321505868.SGD","BK4007","LU0321505439.SGD","SG9999013999.USD","SG9999002224.SGD","BK4568","IE0002270589.USD","LU0868494617.USD","LU0289739699.SGD","LU1894683264.USD"],"gpt_icon":0},{"id":"2528708072","title":"Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2528708072","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528708072?lang=en_us&edition=fundamental","pubTime":"2025-04-17 04:05","pubTimestamp":1744833900,"startTime":"0","endTime":"0","summary":"Conference Call Scheduled for Wednesday, April 23 at 4:30 p.m. Eastern Time. SAN DIEGO, April 16, 2025 /PRNewswire/ --Viking Therapeutics, Inc.  , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter 2025 after the market close on Wednesday, April 23, 2025.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/viking-therapeutics-report-financial-results-200500522.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/viking-therapeutics-report-financial-results-200500522.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","VKTX","BK4139","BK4599","AMN","BK4196","BK4588"],"gpt_icon":0},{"id":"2528322647","title":"Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®","url":"https://stock-news.laohu8.com/highlight/detail?id=2528322647","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528322647?lang=en_us&edition=fundamental","pubTime":"2025-04-16 23:45","pubTimestamp":1744818300,"startTime":"0","endTime":"0","summary":"Saint-Herblain , April 16, 2025 – Valneva SE , a specialty vaccine company, today announced its presence at the forthcoming 25th World Vaccine Congress, which will take place from April 21-24, 2025 at the Walter E. convention center in Washington, D.C. Under the leadership of the Companys Chief Executive Officer, Thomas Lingelbach, a team of Valnevas senior managers will participate in multiple events, including an important presentation on the Companys vaccine IXCHIQ, the world’s first licensed chikungunya vaccine.The Company will have a display in the exhibit area of the congress at booth #424.In the evening of April 22, Valneva will attend the Vaccine Industry Excellence Awards ceremony, where it is a finalist for the Best Biotech Award and Best Prophylactic Vaccine Award for VLA15, the most advanced Lyme disease vaccine candidate worldwide, currently in Phase 3, partnered with Pfizer.About IXCHIQ IXCHIQ is the world’s first licensed chikungunya vaccine available to address this sig","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/valneva-participate-multiple-events-25th-154500336.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999002232.USD","IE000M9KFDE8.USD","INRLF","LU0868494617.USD","LU1894683264.USD","IE00BLSP4239.USD","SGXZ57979304.SGD","IE00BLSP4452.SGD","LU0321505439.SGD","BK4568","LU0234572021.USD","LU1057294990.SGD","BK4139","BK4534","IE00B19Z3581.USD","LU0058720904.USD","LU0456855351.SGD","SG9999002224.SGD","BK4599","LU0289739699.SGD","BK4007","LU0985481810.HKD","VALN","SG9999011175.SGD","SG9999013999.USD","LU0170899867.USD","LU0321505868.SGD","IE00B19Z3B42.SGD","BK4588","BK4585","LU0122379950.USD","LU0306807586.USD","IE0002270589.USD","BK4533","BK4581","LU1883839398.USD","LU1023059063.AUD","BK4592","IE00BBT3K403.USD","LU0306806265.USD","SG9999001176.SGD","LU0225284248.USD","LU1066053197.SGD","LU1066051498.USD","SG9999003800.SGD","SG9999001176.USD","LU0225771236.USD","LU1894683348.USD","BK4550"],"gpt_icon":1},{"id":"2527225559","title":"Top Cancer Stocks to Buy to Boost Your Portfolio's Health","url":"https://stock-news.laohu8.com/highlight/detail?id=2527225559","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527225559?lang=en_us&edition=fundamental","pubTime":"2025-04-16 21:45","pubTimestamp":1744811100,"startTime":"0","endTime":"0","summary":"An updated edition of the March 7, 2025, article.The cancer market is seeing significant growth and evolution as there is a rising demand for targeted, less toxic cancer medicines. According to the American Cancer Society, 2024 was the first time that new cancer cases in the United States were expected to cross the 2-million mark. This resulted in a massive increase in the global spending on cancer medicines.Verastem Oncology’s new drug application  seeking approval of its novel combination regimen of avutometinib plus defactinib for treating KRAS mutant recurrent low-grade serous ovarian cancer , a rare and distinct type of ovarian cancer, is under priority review with the FDA. The FDA’s decision on the NDA is expected on June 30, 2025. Avutometinib is an RAF/M","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/top-cancer-stocks-buy-boost-134500112.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0795875169.SGD","LU0820561818.USD","LU0306806265.USD","MBC","LU1066051498.USD","IE00BVYPNW00.USD","LU0456855351.SGD","BK4107","L","LU0029864427.USD","LU0949170772.SGD","SG9999002232.USD","IE00BFTCPJ56.SGD","LU1894683264.USD","PYXS","BK4534","LU1003077747.HKD","LU0321505439.SGD","LU0203347892.USD","LU1023059063.AUD","LU0795875086.SGD","SGXZ57979304.SGD","LU1496350171.SGD","LU2462157665.USD","LU1244550221.USD","LU2237443465.HKD","AZN","ABBV","VSTM","LU2237443622.USD","LU0310800379.SGD","LU1496350502.SGD","LU1839511570.USD","RLAY","LU0868494617.USD","LU0912757837.SGD","LU0320765992.SGD","BK4588","NVS","LU2089984988.USD","LU0203345920.USD","LU1057294990.SGD","LU1093756168.USD","IE00BJT1NW94.SGD","LU2417539215.USD","BK4599","BK4550","LU1934455863.HKD","LU0234570918.USD"],"gpt_icon":1},{"id":"2527251342","title":"Viking Therapeutics’ VK2735: A Promising Contender Amidst Pfizer’s Setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2527251342","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527251342?lang=en_us&edition=fundamental","pubTime":"2025-04-16 15:35","pubTimestamp":1744788926,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Thomas Smith has maintained their bullish stance on VKTX stock, giving a Buy rating on April 14. Thomas Smith’s rating is ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/viking-therapeutics-vk2735-a-promising-contender-amidst-pfizers-setback?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/viking-therapeutics-vk2735-a-promising-contender-amidst-pfizers-setback?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0306807586.USD","BK4592","LU0058720904.USD","LU1894683348.USD","LU0122379950.USD","LU0234572021.USD","LU1066053197.SGD","LU1023059063.AUD","SG9999001176.SGD","SGXZ57979304.SGD","LU1066051498.USD","SG9999002224.SGD","SG9999002232.USD","IE00BLSP4452.SGD","SG9999013999.USD","LU0985481810.HKD","BK4139","LU0225771236.USD","BK4568","VKTX","BK4581","LU1057294990.SGD","IE0002270589.USD","SG9999001176.USD","BK4585","LU0170899867.USD","IE00BBT3K403.USD","LU1883839398.USD","IE00B19Z3581.USD","BK4007","LU0225284248.USD","LU0289739699.SGD","BK4588","LU0456855351.SGD","IE00B19Z3B42.SGD","LU0868494617.USD","IE00BLSP4239.USD","LU0321505868.SGD","SG9999003800.SGD","LU0321505439.SGD","LU0306806265.USD","SG9999011175.SGD","BK4550","BK4533","LU1894683264.USD","IE000M9KFDE8.USD","BK4534","BK4599"],"gpt_icon":0},{"id":"2527515475","title":"Trump signs healthcare executive order that includes a win for pharma companies","url":"https://stock-news.laohu8.com/highlight/detail?id=2527515475","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527515475?lang=en_us&edition=fundamental","pubTime":"2025-04-16 05:34","pubTimestamp":1744752889,"startTime":"0","endTime":"0","summary":"Trump signs healthcare executive order that includes a win for pharma companiesTrump's order targets Medicare drug price negotiation timelineCongress must approve changes to Medicare price negotiationsOrder encourages state drug importation programsFDA urged to streamline approval for generics and biosimilarsBy Ahmed Aboulenein","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nL1N3QT0VS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BLSP4452.SGD","BK4599","LU0122379950.USD","IE00BBT3K403.USD","LU0306807586.USD","BK4585","LU0234572021.USD","BK4592","LU0321505868.SGD","LU0985481810.HKD","SG9999002232.USD","LU0170899867.USD","IE00B19Z3B42.SGD","LU1883839398.USD","SG9999011175.SGD","LU0456855351.SGD","LU1023059063.AUD","BK4588","LU0868494617.USD","SG9999001176.SGD","IE000M9KFDE8.USD","BK4581","IE00B19Z3581.USD","LU0225771236.USD","BK4533","LU0058720904.USD","BK4568","IE0002270589.USD","LU1057294990.SGD","BK4550","LU1894683264.USD","BK4534","SG9999002224.SGD","SG9999013999.USD","IE00BLSP4239.USD","LU1066053197.SGD","LU0321505439.SGD","LU0289739699.SGD","LU1894683348.USD","SG9999001176.USD","SGXZ57979304.SGD","SG9999003800.SGD","BK4007","LU0306806265.USD","LU1066051498.USD","LU0225284248.USD"],"gpt_icon":1},{"id":"2527475591","title":"Trump Signs Healthcare Executive Order Seeking Changes to US Medicare Drug Price Negotiation Process","url":"https://stock-news.laohu8.com/highlight/detail?id=2527475591","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527475591?lang=en_us&edition=fundamental","pubTime":"2025-04-16 05:34","pubTimestamp":1744752889,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nL1N3QT0VS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0289739699.SGD","LU0122379950.USD","LU1066053197.SGD","IE00BBT3K403.USD","SG9999011175.SGD","LU0456855351.SGD","LU1023059063.AUD","LU0868494617.USD","BK4568","LU1057294990.SGD","SG9999013999.USD","BK4533","PFE","BK4581","IE00B19Z3B42.SGD","SG9999001176.SGD","LU0170899867.USD","BK4585","LU0234572021.USD","LU0321505868.SGD","LU1894683348.USD","IE0002270589.USD","BK4007","LU1066051498.USD","LU1894683264.USD","BK4599","SG9999003800.SGD","LU0225771236.USD","LU1883839398.USD","LU0321505439.SGD","IE000M9KFDE8.USD","BK4534","LU0225284248.USD","BK4588","IE00BLSP4452.SGD","SGXZ57979304.SGD","BK4592","LU0306806265.USD","IE00B19Z3581.USD","SG9999002232.USD","LU0306807586.USD","IE00BLSP4239.USD","BK4550","SG9999001176.USD","LU0058720904.USD","LU0985481810.HKD","SG9999002224.SGD"],"gpt_icon":0},{"id":"2527723473","title":"Counterfeit Ozempic Identified in US Supply Chain With Fake Labels And Needles, FDA Alerts","url":"https://stock-news.laohu8.com/highlight/detail?id=2527723473","media":"Benzinga","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527723473?lang=en_us&edition=fundamental","pubTime":"2025-04-16 04:20","pubTimestamp":1744748435,"startTime":"0","endTime":"0","summary":"On Monday, Novo Nordisk A/S  said it had become aware of several hundred units of Ozempic injection 1 mgdistributed outside the Novo Nordisk authorized supply chain in the U.S.The seized counterfeit products featurelot number PAR0362 and illegitimate serial numbers beginning with the first eight digits 51746517.Also Read: Eli Lilly And Novo Nordisk Could Face Policy Shifts As FDA Oversight, Tariff Risks Mount. The U.S. Food and Drug Administration  says that further analyses, including extensive visual examination and chemical testing of the seized counterfeit product, are underway as the investigation continues.Accordingly, neither NovoNordisk nor the FDA can confirm the contents or quality of the counterfeit product, which may present a safety risk for patients who use the counterfeit product.FDA and Novo Nordisk are testing the seized products and do not yet have information about the drugs' identity, quality, or safety.FDA is aware of six adverse events from this lot, none of which","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/counterfeit-ozempic-identified-us-supply-202035878.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","IE00BZ1G4Q59.USD","BK4599","IE00BKVL7J92.USD","LU1093756168.USD","BK4585","BK4588","BK4532","LU1093756325.SGD","NVO","LU0154236417.USD"],"gpt_icon":1},{"id":"2527142930","title":"European pharma companies issue demands to stay in EU ahead of expected US tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2527142930","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527142930?lang=en_us&edition=fundamental","pubTime":"2025-04-16 02:27","pubTimestamp":1744741620,"startTime":"0","endTime":"0","summary":"European pharma companies issue demands to stay in EU ahead of expected US tariffs PARIS, April 15 (Reuters) - Nearly three dozen global pharmaceutical companies, in a letter to the head of the Europe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nL1N3QT0TM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306807586.USD","LU2237443465.HKD","PFE","LU2461242641.AUD","LU2602419157.SGD","SGXZ31699556.SGD","LU0114720955.EUR","LU1035775433.USD","LU1989771016.USD","LU2471134952.CNY","BK4599","SG9999002232.USD","IE00B3T34201.USD","LU1280957306.USD","LU2237443549.SGD","LU2023250504.SGD","LU0061475181.USD","03165","LU2264538146.SGD","IE00BFTCPJ56.SGD","LU0575583348.USD","LU0109391861.USD","BK4007","LU0496365809.HKD","LU2491049909.HKD","SG9999011175.SGD","LU0029864427.USD","LU1267930573.SGD","LU0784385840.USD","AZN.UK","LU1051770623.HKD","LU1712237335.SGD","LU1868836914.USD","LU0889565080.SGD","LU1551013425.SGD","IE0004445239.USD","LLY","SG9999018857.SGD","LU2089284900.SGD","LU1003077747.HKD","LU1880407215.USD","LU0047473722.SGD","LU0456855351.SGD","LU0466842654.USD","LU0385154629.USD","LU1323610961.USD","LU0972486137.USD","LU0203202063.USD","LU0661504455.SGD","LU1868836591.USD"],"gpt_icon":1},{"id":"2527444107","title":"NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2527444107","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527444107?lang=en_us&edition=fundamental","pubTime":"2025-04-15 22:00","pubTimestamp":1744725600,"startTime":"0","endTime":"0","summary":"Obesity stocks like Novo Nordisk NVO, Eli Lilly LLY, Structure Therapeutics GPCR and Viking Therapeutics VKTX gained 2.1%, 3%, 10.6% and 19.2%, respectively, on Monday after pharma bigwig Pfizer PFE announced that it is discontinuing the development of its GLP-1R weight loss pill, danuglipron.After reviewing all clinical data and considering regulatory feedback, Pfizer concluded that halting the program was the best course of action. This decision reverted Pfizer’s developmental program for an obesity candidate back to the early clinical stages and has significantly delayed its hopes for marketing an obesity drug that would compete with Lilly’s Zepbound and Novo Nordisk’s Wegovy for market share.How PFE’s Obesity Study Setback Benefits VKTX, GPCR, LLY & NVO. Shares of Lilly, Novo Nordisk, Viking Therapeutics and Structure Therapeutics rose as Pfizer's decision to discontinue its obesity pill program removes a ke","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nvo-lly-gpcr-vktx-stocks-140000975.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2361044865.SGD","LU0354030438.USD","SG9999014914.USD","BK4581","LU0672654240.SGD","LU2552382058.USD","LU1868837300.USD","LU1551013425.SGD","BK4568","LU0058720904.USD","IE00BJT1NW94.SGD","LU1232071149.USD","LU0820561909.HKD","BK4599","LU1868836757.USD","LU1291159041.SGD","BK4532","LU1127390331.HKD","IE000M9KFDE8.USD","LU1883839398.USD","LU2471134952.CNY","LU0203202063.USD","GPCR","LU1069344957.HKD","SGXZ99366536.SGD","LU0456855351.SGD","LU1093756325.SGD","LU1894683348.USD","IE0002141913.USD","LU1712237335.SGD","LU0985481810.HKD","NVO","LU0289739699.SGD","LU0882574055.USD","VKTX","PFE","LU0868494617.USD","LU0106261372.USD","SGXZ81514606.USD","IE00BZ1G4Q59.USD","IE00BLSP4452.SGD","LU2237443465.HKD","BK4588","SG9999011175.SGD","LU0096364046.USD","LU1917777945.USD","LU1983299246.USD","LU2360106947.USD","LLY","SG9999013999.USD"],"gpt_icon":1},{"id":"2527416458","title":"BRIEF-Skye Bioscience Demonstrates Over 30% Weight Loss With Nimacimab And Tirzepatide Combination In Preclinical Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2527416458","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527416458?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:51","pubTimestamp":1744721470,"startTime":"0","endTime":"0","summary":"BRIEF-Skye Bioscience Demonstrates Over 30% Weight Loss With Nimacimab And Tirzepatide Combination In Preclinical ModelApril 15 (Reuters) - Eli Lilly and Co LLY.N:SKYE BIOSCIENCE DEMONSTRATES OVER 30%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nTUA5SCWWV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0466842654.USD","LU0061475181.USD","LU2264538146.SGD","BK4516","SG9999014898.SGD","LU1804176565.USD","LU0106261372.USD","BK4007","IE00B1BXHZ80.USD","LU2211815571.USD","LU2237443465.HKD","SGXZ81514606.USD","LU0820561818.USD","LU1720051017.SGD","LU2324357040.USD","SG9999015978.USD","SG9999001176.USD","LU2552382132.HKD","LU2491049909.HKD","LU2471134523.USD","LU1093756325.SGD","SKYE","LU1093756168.USD","LU0823416689.USD","LU0354030438.USD","SG9999015986.USD","IE00BJT1NW94.SGD","SGXZ57979304.SGD","LU1069344957.HKD","LU0471298694.HKD","LU1623119135.USD","SG9999015952.SGD","LU1064131342.USD","LU1989771016.USD","LU0385154629.USD","LU1280957306.USD","LU0094547139.USD","BK4599","LU2602419157.SGD","LU0708995401.HKD","LU1868836914.USD","LU2361045086.USD","LU2468319806.SGD","LU2491050071.SGD","LU1974910355.USD","SG9999018865.SGD","LU1232071149.USD","LU0354030511.USD","LU2106854487.HKD"],"gpt_icon":1},{"id":"2527139244","title":"BUZZ-Skye Bioscience rises after experimental weight-loss drug shows promise in mice","url":"https://stock-news.laohu8.com/highlight/detail?id=2527139244","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527139244?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:20","pubTimestamp":1744719634,"startTime":"0","endTime":"0","summary":"BUZZ-Skye Bioscience rises after experimental weight-loss drug shows promise in mice** Shares of drug developer Skye Bioscience SKYE.O rise 11.5% to $1.46 premarket** Co says its drug candidate, nimacimab, showed 23.5% weight loss in mice, comparable to Eli Lilly's LLY.N popular drug, tirzepatide, sold as Zepbound, and Novo Nordisk's NOVOb.CO experimental drug, monlunabant** SKYE also says nimacimab, when combined with tirzepatide, showed a greater than 30% weight loss** Initial data from SKYE's mid-stage study in obesity is expected in late Q3/early Q4 2025** Up to last close, stock had fallen 53.7% YTD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nL6N3QT0KJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","LU1551013342.USD","LU1623119135.USD","IE00BFTCPJ56.SGD","IE0002141913.USD","LU1917777945.USD","LU1974910355.USD","LU1127390331.HKD","LU1814569148.SGD","SG9999015952.SGD","SKYE","BK4588","LU2237443382.USD","LU2237443978.SGD","LU1069344957.HKD","LU0203202063.USD","LU2471134523.USD","BK4139","SGXZ51526630.SGD","IE00BK4W5L77.USD","BK4516","SGXZ57979304.SGD","LU1280957306.USD","LU1868836914.USD","LU2471134952.CNY","SG9999018865.SGD","LU0820561818.USD","LU2237443465.HKD","LU0417517546.SGD","LU1551013425.SGD","LU1712237335.SGD","LU0456855351.SGD","LU1983299246.USD","SG9999015978.USD","IE00BJJMRZ35.SGD","BK4599","LU1366192091.USD","IE00BK4W5M84.HKD","IE00BJT1NW94.SGD","SG9999014914.USD","LU2265009873.SGD","LU0061475181.USD","LU0079474960.USD","SG9999017495.SGD","LU2063271972.USD","LU0943347566.SGD","BK4581","LU1061106388.HKD","LU0471298777.SGD"],"gpt_icon":1},{"id":"2527146274","title":"Eli Lilly and Company (LLY): One of the High Growth Forever Dividend Stocks to Invest In","url":"https://stock-news.laohu8.com/highlight/detail?id=2527146274","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527146274?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:48","pubTimestamp":1744717684,"startTime":"0","endTime":"0","summary":"We recently published a list of the10 High Growth Forever Dividend Stocks to Invest In. In this article, we are going to take a look at where Eli Lilly and Company  stands against other high growth forever dividend stocks.Dividend stocks have trailed the broader market over the past two years, largely due to investors favoring AI-focused companies. Still, experienced investors recognize the long-term value of dividend-paying stocks, supported by their strong historical performance. Short-term trends don’t diminish their importance. In fact, dividends have historically played a major role in total returns, accounting for about 31% of the broader market’s monthly total return from 1926 through February 2025, according to S&P Dow Jones Indices.The report emphasized that the most promising opportunities in the dividend space lie with so-called “Compounders","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/eli-lilly-company-lly-one-114804634.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1868836914.USD","IE0004445239.USD","LU1069344957.HKD","LU2750360641.GBP","IE00BJJMRZ35.SGD","LU1064131342.USD","LU1868837300.USD","BK4516","LU1127390331.HKD","LU0203201768.USD","LU1366192091.USD","LU2360106947.USD","LU2468319806.SGD","LU0058720904.USD","SG9999018865.SGD","LU0256863902.USD","IE0009355771.USD","LU0820561818.USD","BK4599","LU0289739699.SGD","BK4007","LU1093756168.USD","LU2552382132.HKD","LU1551013425.SGD","LU2237443978.SGD","LU2491049909.HKD","SG9999015986.USD","SG9999014906.USD","LU0882574055.USD","LU2324357040.USD","IE0002141913.USD","BK4581","LU0109391861.USD","IE00BFTCPJ56.SGD","BK4533","LU0820561909.HKD","LU0689472784.USD","LU2750360997.AUD","LU0708995401.HKD","LU2063271972.USD","LU2237443549.SGD","LLY","LU0417517546.SGD","LU1814569148.SGD","LU1868837136.USD","SG9999001176.USD","LU0061475181.USD","LU1720051017.SGD","SG9999017495.SGD","LU1551013342.USD"],"gpt_icon":1}],"pageSize":20,"totalPage":8,"pageCount":3,"totalSize":157,"code":"91000000","status":"200"}]}}